News
Cancer
Molecule driving brain cancer cell survival could lead to fu...
Glioblastoma patients have poor survival rates, partly due to the cancer’s unique abi...
Dr Rachel Perret: Back home to take CAR T to the next level
Twelve years ago, Dr Perret packed her bags for Europe, having recently completed her...
CAR T-cell supporter David Downs semi-finalist for New Zeala...
David, who was diagnosed with non-Hodgkin lymphoma in 2017, ultimately travelled to B...
Marsden funding for CAR T-cell research into solid tumours
In its latest round of funding, Te Pūtea Rangahau a Marsden, the Marsden Fund, has al...
New Zealand’s first CAR T-cell cancer therapy clinical trial...
New Zealand’s first clinical trial of CAR T-cell therapy, a revolutionary new approac...
International collaboration to improve cancer therapy finds ...
Recently published in the journal Redox Biology, the research team found that prior t...
Government matches Malaghan Institute’s ambitions for cancer...
The Ministry of Business, Innovation and Employment’s Partnership Scheme will contrib...
Immunotherapy profoundly changing the way we treat cancer
Director of the Malaghan Institute of Medical Research Professor Graham Le Gros says...
Nobel Prize recognises growing relevance of immunotherapy in...
The decision to award a Nobel Prize to two leading immunotherapy researchers is well ...
Scope 66 - David Downs: CAR T-cell recipient
David Downs, cancer survivor and self-declared ‘genetically modified organism’ recent...